MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA

BACKGROUND: Detection of glioma with MRI contrast agent is limited to cases in which the blood-brain barrier (BBB) is compromised as contrast agents cannot cross the BBB. Thus, an early-stage infiltrating tumor is not detectable. Interleukin-13 receptor alpha 2 (IL-13Rα2), which has been shown to be...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Liu, Xiaoli, Madhankumar, Achuthamangalam B., Miller, Patti A., Duck, Kari A., Hafenstein, Susan, Rizk, Elias, Slagle-Webb, Becky, Sheehan, Jonas M., Connor, James R., Yang, Qing X.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2016
Matèries:
Basic and Translational Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4827043/
https://ncbi.nlm.nih.gov/pubmed/26519740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nov263
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars